HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome.

Abstract
The aim of this retrospective analysis was to evaluate feasibility and effectiveness of definitive chemoradiotherapy without split-course technique in anal cancer patients. From 1993 to 2003, 81 patients were treated; 13 were excluded due to various chemotherapeutic regimes, thus 68 patients were analysed. In case of acute grade 3 toxicities, treatment was halted until improvement or resolution independent of dose. Short interruption was defined as completing treatment without exceeding eight cumulative treatment days beyond scheduled plan, other patients were considered to have had prolonged interruption. Median follow-up was 46 months. Median overall treatment time was 53 days corresponding to an interruption of eight cumulative treatment days. Thirty-five patients (51%) had treatment interruption of <or=8 days. No acute grade 4 toxicities were observed; one fatality occurred during treatment due to ileus-like symptoms according to acute grade 5 toxicity. Comparing patients with short vs. prolonged interruption 5-year actuarial rates for local control were 85% vs. 81% (p = 0.605) and for colostomy-free survival 85% vs. 87% (p = 0.762), respectively. Chemoradiotherapy with short individualised treatment interruptions seems to be feasible with acceptable acute or late toxicities. Treatment is highly effective in terms of local control and colostomy-free survival.
AuthorsAndreas Meyer, Jürgen Meier Zu Eissen, Johann H Karstens, Michael Bremer
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 45 Issue 6 Pg. 728-35 ( 2006) ISSN: 0284-186X [Print] England
PMID16938816 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Semustine
  • Cyclophosphamide
  • Melphalan
  • Fluorouracil
Topics
  • Adult
  • Aged
  • Analysis of Variance
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Anus Neoplasms (drug therapy, radiotherapy)
  • Cyclophosphamide (therapeutic use)
  • Dose Fractionation, Radiation
  • Female
  • Fluorouracil (therapeutic use)
  • Humans
  • Male
  • Melphalan (therapeutic use)
  • Middle Aged
  • Radiotherapy Dosage
  • Retrospective Studies
  • Semustine (therapeutic use)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: